Ibritumomab

Brand names: Zevalin · Active ingredient: Ibritumomab Tiuxetan

In short: Zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). Zevalin is indicated for the treatment of previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line

Forms & strengthsInjection: 3.2 mg ibritumomab tiuxetan per 2 mL as a clear, colorless solution, that may contain translucent particles, in a single-dose vial.
LabelAcrotech Biopharma Inc
Label updatedApr 26, 2023

What is Ibritumomab used for?

Zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).

Zevalin is indicated for the treatment of previously untreated follicular NHL in adult patients who achieve a partial or complete response to first-line chemotherapy.

âš  Boxed warning (FDA's strongest warning)

Serious Infusion Reactions: Deaths have occurred within 24 hours of rituximab infusion, an essential component of the Zevalin therapeutic regimen. These fatalities were associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. Most (80%) fatalities occurred with the first rituximab infusion . Discontinue rituximab and Y-90 Zevalin infusions in patients who develop severe infusion reactions.

Prolonged and Severe Cytopenias: Y-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Do not administer Y-90 Zevalin to patients with ≥ 25% lymphoma marrow involvement and/or impaired bone marrow reserve .

Severe Cutaneous and Mucocutaneous Reactions: Severe cutaneous and mucocutaneous reactions, some fatal, can occur with the Zevalin therapeutic regimen. Discontinue rituximab and Y-90 Zevalin infusions in patients experiencing severe cutaneous or mucocutaneous reactions .

Dosing: The dose of Y-90 Zevalin should not exceed 32 mCi (1184 MBq) .

Ibritumomab dosage

Administer the Zevalin therapeutic regimen as outlined below.

Initiate the Zevalin therapeutic regimen following recovery of platelet counts to 150,000/mm3 or more at least 6 weeks, but no more than 12 weeks, following the last dose of first-line chemotherapy.

Only administer rituximab/Zevalin in facilities where immediate access to resuscitative measures is available.

Overview of Dosing Schedule

Day 1:

Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally prior to rituximab infusion.

Administer rituximab 250 mg/m2 intravenously at an initial rate of 50 mg/hr. In the absence of infusion reactions, escalate the infusion rate in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. Do not mix or dilute rituximab with other drugs.

Immediately stop the rituximab infusion for serious infusion reactions and discontinue the Zevalin therapeutic regimen .

Temporarily slow or interrupt the rituximab infusion for less severe infusion reactions. If symptoms improve, continue the infusion at one-half the previous rate.

Day 7, 8 or 9:

Premedicate with acetaminophen 650 mg orally and diphenhydramine 50 mg orally prior to rituximab infusion.

Administer rituximab 250 mg/m2 intravenously at an initial rate of 100 mg/hr. Increase rate by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr, as tolerated. If infusion reactions occurred during rituximab infusion on Day 1 of treatment, administer rituximab at an initial rate of 50 mg/hr and escalate the infusion rate in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.

Administer Y-90 Zevalin injection through a free flowing intravenous line within 4 hours following completion of rituximab infusion. Use a 0.22 micron low-protein-binding in-line filter between the syringe and the infusion port. After infusion, flush the line with at least 10 mL of normal saline.

If platelet count at least 150,000/mm3

, administer Y-90 Zevalin over 10 minutes as an intravenous infusion at a dose of Y-90 0.4 mCi per kg (14.8 MBq per kg) actual body weight.

If platelet count 100,000 to 149,000/mm3

, in relapsed or refractory patients, administer Y-90 Zevalin over 10 minutes as an intravenous infusion at a dose of Y-90 0.3 mCi per kg (11.1 MBq per kg) actual body weight.

Do not administer more than 32 mCi (1184 MBq) Y-90 Zevalin dose regardless of the patient’s body weight.

Monitor patients closely for evidence of extravasation during the infusion of Y-90 Zevalin. Immediately stop infusion and restart in another limb if any signs or symptoms of extravasation occur .

A clearly-labeled kit is required for preparation of Yttrium-90 (Y-90) Zevalin. Follow the detailed instructions for the preparation of radiolabeled Zevalin . …

How to take Ibritumomab — instructions & advice from the label

Advise patients:

To contact a healthcare professional for severe signs and symptoms of infusion reactions.

To take premedications as prescribed .

To report any signs or symptoms of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatigue) .

To avoid medications that interfere with platelet function, except as directed by a healthcare professional .

To seek prompt medical evaluation for diffuse rash, bullae, or desquamation of the skin or oral mucosa .

To immediately report symptoms of infection (e.g. pyrexia) .

That immunization with live viral vaccines is not recommended for 12 months following the Zevalin therapeutic regimen .

To use effective contraceptive methods during treatment and for a minimum of 12 months following Zevalin therapy , Use in Specific Populations (8.1, 8.3) and Nonclinical Toxicology (13.1)].

To discontinue breastfeeding during and for 6 months after the last dose of Zevalin treatment .

Zevalin ® (ibritumomab tiuxetan)

Manufactured by: Acrotech Biopharma Inc. East Windsor, NJ 08520 U.S. License No.2159

Zevalin ® is a registered trademark of Acrotech Biopharma Inc and its subsidiaries.

Protected by U.S. Patent Nos. …

Warnings & precautions

Do not take this medicine if: None.

Rituximab, alone or as a component of the Zevalin therapeutic regimen, can cause severe, including fatal, infusion reactions. These reactions typically occur during the first rituximab infusion with time to onset of 30 to 120 minutes. Signs and symptoms of severe infusion reactions may include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, and cardiogenic shock. Temporarily slow or interrupt the rituximab infusion for less severe infusion reactions. Immediately discontinue rituximab and Y-90 Zevalin administration for severe infusion reactions. Only administer rituximab/Zevalin in facilities where immediate access to resuscitative measures is available . See also prescribing information for rituximab.

Cytopenias with delayed onset and prolonged duration, some complicated by hemorrhage and severe infection, are the most common severe adverse reactions of the Zevalin therapeutic regimen. When used according to recommended doses, the incidences of severe thrombocytopenia and neutropenia are greater in patients with mild baseline thrombocytopenia (≥ 100,000 but ≤ 149,000/mm3) compared to those with normal pretreatment platelet counts. Severe cytopenias persisting more than 12 weeks following administration can occur. Monitor complete blood counts (CBC) and platelet counts following the Zevalin therapeutic regimen weekly until levels recover or as clinically indicated .

Do not administer the Zevalin therapeutic regimen to patients with ≥ 25% lymphoma marrow involvement and/or impaired bone marrow reserve. Monitor patients for cytopenias and their complications (e.g., febrile neutropenia, hemorrhage) for up to 3 months after use of the Zevalin therapeutic regimen. …

Ibritumomab side effects

The following serious adverse reactions are discussed in greater detail in other sections of the label:

Serious Infusion Reactions .

Prolonged and Severe Cytopenias .

Severe Cutaneous and Mucocutaneous Reactions .

Leukemia and Myelodysplastic Syndrome .

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The reported safety data reflects exposure to Zevalin in 349 patients with relapsed or refractory, low-grade, follicular or transformed NHL across 5 trials (4 single arm and 1 randomized) and in 206 patients with previously untreated follicular NHL in a randomized trial (FIT study) who received any portion of the Zevalin therapeutic regimen. The safety data reflect exposure to Zevalin in 270 patients with relapsed or refractory NHL with platelet counts ≥150,000/ mm3 who received 0.4 mCi/kg (14.8 MBq/kg) of Y-90 Zevalin (Group 1 in Table 4), 65 patients with relapsed or refractory NHL with platelet counts of ≥ 100,000 but ≤ 149,000 /mm3 who received 0.3 mCi/kg (11.1 MBq/kg) of Y-90 Zevalin (Group 2 in Table 4), and 204 patients with previously untreated NHL with platelet counts ≥150,000/ mm3 who received 0.4 mCi/kg (14.8 MBq/kg) of Y-90 Zevalin; all patients received a single course of Zevalin. …

Drug interactions

Patients receiving medications that interfere with platelet function or coagulation should have more frequent laboratory monitoring for thrombocytopenia. No formal drug interaction studies have been performed with Zevalin.

About this medicine

Zevalin (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan [N-[2-bis(carboxymethyl) amino]-3-(p-isothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2- (methyl)-ethyl]glycine. This linker-chelator provides a high affinity, conformationally restricted chelation site for Yttrium-90. The approximate molecular weight of ibritumomab tiuxetan is 148 kD. The antibody moiety of Zevalin is ibritumomab, a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen.

Ibritumomab tiuxetan is a clear, colorless, sterile, pyrogen-free, preservative-free solution that may contain translucent particles. Each single-use vial includes 3.2 mg of ibritumomab tiuxetan in 2 mL of 0.9% Sodium Chloride.

Physical/Radiochemical Characteristics of Y-90

Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours (2.67 days). The product of radioactive decay is non-radioactive Zirconium-90. The range of beta particles in soft tissue (χ90) is 5 mm. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 25d367dc-da65-44c9-a844-1bf15339c285. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate